- Investor's Business Daily•3 days ago
Merck and Roche are swiping share from Bristol-Myers Squibb's I-O drugs after their FDA approvals in advanced lung cancer.
- Reuters•8 days ago
Swiss pharmaceuticals company Roche said on Saturday that a combination of its immunotherapy drug Tecentriq and its blockbuster cancer drug Avastin had shown encouraging results in a Phase II trial in treating a type of kidney cancer. The study found that the combination had a "manageable safety profile" when used for locally advanced or metastatic renal cell carcinoma (mRCC). The tests showed promising effectiveness compared with the standard treatment for mRCC, sunitinib, which is sold by Pfizer under the brand name Sutent.
- Investor's Business Daily•9 days ago
A handful of products define the new market for drugs that harness the immune system to fight cancer. Here's a list of the drugs and their FDA-approved uses.
RHO.DU : Summary for ROCHE HLDG AG INH. SF 1 - Yahoo Finance
ROCHE HLDG AG INH. SF 1 (RHO.DU)
Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
Add to watchlist
At close: 8:27AM CET
|Day's Range||231.33 - 231.33|
|52 Week Range||227.53 - 234.27|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|